Keywords: bristol-myers, squibb, schering-plough, co-promote, tequin, announced, co-promotiondeal
Bristol-Myers Squibb, Schering-Plough to co-promote Tequin
Article | 15 March 2000
Bristol-Myers Squibb and Schering-Plough have announced a co-promotiondeal for the former's broad-spectrum fluoroquinolone antibiotic Tequin (gatifloxacin) in the USA.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
